Ripple Science Signs Its One-Hundredth Customer: Company inks multi-year deal with Ora, leading ophthalmology CRO
Ripple Science signs the world's leading full-service ophthalmic Clinical Research Organization, Ora, Inc., as its one hundredth customer. With Ripple, Ora will centralize patient recruitment in order to improve efficiency at clinical trial sites.
Utilizing Ripple’s offerings to bring recruiting in-house will enable us to gain performance visibility across all clinical sites.
ANN ARBOR, MICH. (PRWEB) JANUARY 23, 2020
Ripple Science today announced their one-hundredth customer. Ora, Inc., the world’s leading, full-service ophthalmic Clinical Research Organization (CRO), has adopted Ripple SaaS, enabling Ora to centralize patient recruitment in order to improve efficiency at clinical trial sites.
Rod Walker, Sr. Director, Head of Patient and Site Solutions at Ora, commented, "Utilizing Ripple’s offerings to bring recruiting in-house will enable us to gain performance visibility across all clinical sites. This will help to reduce risks and lead to greater retention and accelerated studies, which means better results for our customers.”
“The partnership with Ora represents a significant milestone for Ripple Science which embarked on a mission a year ago to develop product features and functionality specifically for the CRO market," commented Peter Falzon, President and CEO of Ripple Science. "I am pleased that the team continues to achieve key milestones and that Ripple is attracting industry customers that have high expectations."
A long-standing issue for clinical trials failing is the clinical trial site not meeting the recruitment target. Ripple addresses this issue by guiding teams through the recruitment process while providing real-time statistics on enrollment goals. Teams using Ripple hit their enrollment targets and retain participants throughout the duration of their trials.
About Ora, Inc.
Ora is the world’s leading full-service ophthalmic CRO and product development firm with offices in the United States, the United Kingdom, Australia and Japan. Over the past 40 years, we have proudly helped our clients earn more than 45 product approvals. We support a wide array of organizations, from start-ups to global pharmaceutical and device companies, to efficiently bring their new products from concept to market. Ora’s pre-clinical and clinical models, unique methodologies and global regulatory strategies have been refined and proven across thousands of global projects. We bring together the world’s most extensive and experienced team of ophthalmic experts and R&D professionals to maximize the value of new product initiatives.
For more information, please visit http://www.oraclinical.com.
About Ripple Science: Ripple Science accelerates clinical research with its secure, HIPAA-compliant suite of tools. By adapting sales and marketing automation to the process of patient recruitment, Ripple helps our customers recruit more participants, faster and reduces patients lost to follow-up.
Ripple Science’s flagship product, Ripple, is currently being used by research investigators at more than 100 academic and research centers around the world, including Johns Hopkins University, Pennsylvania State University, University of California Los Angeles, the Brain Research Foundation Canada, University of East Anglia (UK), Cognito Therapeutics (Boston, MA) and the University of Michigan.
To learn more, please visit: https://www.ripplescience.com